Experimental Anti-Viral MK-4482 To Treat COVID (Rocky Mountain)

 Initial animal tests of a brand new anti-viral medicine has shown what it may treat or even prevent COVID-19.

This could be the magic bullet which could defeat the anti-vaXXers and even the mutations.

MK-4482 shows potential to prevent and treat SARS-CoV-2 infection.

In a press release the NIH just published this information within the hour.

"The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.

In their study, published in the journal Nature Communications, the scientists found MK-4482 treatment effective when provided up to 12 hours before or 12 hours after infecting the hamsters with SARS-CoV-2. These data suggest that MK-4482 treatment potentially could mitigate high-risk exposures to SARS-CoV-2, and might be used to treat established SARS-CoV-2 infection alone or possibly in combination with other agents. 

The same research group, located at Rocky Mountain Laboratories, part of NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana, developed the hamster model last year to mimic SARS-CoV-2 infection and mild disease in people. The University of Plymouth in the United Kingdom collaborated on these most recent studies."

https://www.nih.gov/news-events/news-releases/experimental-antiviral-covid-19-effective-hamster-study


Comments

Unknown said…
This looks very interesting. A quick "Duck" search found that human trials showed a positive effect in early interventions (https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/). As suggested from the original article, it was not very effective in hospitalized patients.

Popular posts from this blog

Does Anyone Still Answer Their Phone?

Climate Change, Too Late To Beg Politicians - Time To Follow The Pentagon And Begin Preparation For The Inevitable.

Nature Magazine Says No COVID-19 Herd Immunity. Also, NO FLU was bad news.